Prosensa Holding Now Covered by Oppenheimer (RNA)
Oppenheimer initiated coverage on shares of Prosensa Holding (NYSE:RNA) in a research note issued on Thursday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock.
Prosensa Holding (NYSE:RNA) traded down 3.61% during mid-day trading on Thursday, hitting $9.87. 86,706 shares of the company’s stock traded hands. Prosensa Holding has a 1-year low of $3.43 and a 1-year high of $34.22. The stock has a 50-day moving average of $10.69 and a 200-day moving average of $7.69. The company’s market cap is $355.1 million.
Prosensa Holding (NYSE:RNA) last issued its quarterly earnings data on Tuesday, May 20th. The company reported $0.26 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.25.
Several other analysts have also recently commented on the stock. Analysts at Roth Capital upgraded shares of Prosensa Holding from a “neutral” rating to a “buy” rating in a research note on Monday. They now have a $17.00 price target on the stock, up previously from $12.00. Finally, analysts at KBC Securities upgraded shares of Prosensa Holding from a “hold” rating to an “accumulate” rating in a research note on Wednesday, June 4th. They now have a $11.00 price target on the stock, up previously from $7.00. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $11.70.
Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (NYSE:RNA)-modulating, therapeutics for the treatment of genetic disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.